Lasa Supergenerics has notified the stock exchanges of an upcoming board meeting, scheduled for Friday, May 29, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, referenced as LASA/SE/26-27/05 and dated Tuesday, May 19, 2026, was submitted to both BSE Limited and the National Stock Exchange of India Limited.

Board Meeting Agenda

The board meeting has been convened to address the following key items:

• Consideration, approval, and recording of the audited financial results of the company for the quarter and the year ended March 31, 2026
• Discussion of any other matter with the permission of the Chairperson

The following table summarises the key details of the scheduled board meeting:

Trading Window Closure

In line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct, the trading window for Lasa Supergenerics shares will continue to remain closed until 48 hours after the declaration of the audited financial results for the quarter and the year ended March 31, 2026. This measure is standard practice to prevent insider trading ahead of material financial disclosures.

Regulatory Disclosures

The board meeting intimation has been made available on the company's official website at www.lasalabs.com , as well as on the websites of the stock exchanges at www.bseindia.com and www.nseindia.com . The intimation was signed by Ganesh Potdar, Director (DIN: 11455401), on behalf of Lasa Supergenerics.

LASA Supergenerics Limited has officially declared to stock exchanges that it falls outside the purview of the Large Corporate category as per SEBI's regulatory framework. The declaration was made pursuant to SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Regulatory Compliance Declaration

The company submitted its declaration to both BSE Limited and National Stock Exchange of India Limited on April 16, 2026. The communication specifically addressed the non-applicability of the Large Entities framework for fund raising through debt securities issuance.

Framework Exemption Status

LASA Supergenerics Limited confirmed that it does not meet the criteria to be classified as a Large Corporate entity under the SEBI framework. This exemption means the company is not subject to the specific compliance requirements and guidelines established for large entities when raising funds through debt securities.

Corporate Communication

The declaration was signed by Ganesh Potdar, Director of the company, with DIN 11455401. The document was digitally signed and submitted to the corporate services departments of both stock exchanges as part of the company's regulatory compliance obligations.

This declaration ensures that LASA Supergenerics Limited maintains transparency with regulatory authorities and stock exchanges regarding its corporate classification status under current SEBI guidelines.